Chromosomal instability in cell-free DNA is a serum biomarker for prostate cancer

Clinical Chemistry

Volumn 61, Issue 1, 2015, Pages 239-248

  Schütz, Ekkehard ^a   Akbari, Mohammad R ^b,c   Beck, Julia ^a   Urnovitz, Howard ^a   Zhang, William W ^c   Bornemann Kolatzki, Kirsten ^a   Mitchell, William M ^d   Nam, Robert K ^c   Narod, Steven A ^b,c  

^a Chronix Biomedical   (Germany)

^b WOMEN S COLLEGE HOSPITAL   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

^d VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DNA; KALLIKREIN; KALLIKREIN-RELATED PEPTIDASE 3, HUMAN; PROSTATE SPECIFIC ANTIGEN; TUMOR MARKER;

AGED; ARTICLE; CANCER CELL; CANCER PATIENT; CHROMOSOMAL INSTABILITY; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; DIAGNOSTIC VALUE; GENOMIC INSTABILITY; GLEASON SCORE; HUMAN; HUMAN GENOME; MAJOR CLINICAL STUDY; MALE; PLOIDY; PROSTATE CANCER; PROSTATE CARCINOMA; PROSTATE HYPERTROPHY; PROSTATITIS; SERUM; ADULT; BLOOD; CANCER GRADING; CASE CONTROL STUDY; COPY NUMBER VARIATION; GENETIC HETEROGENEITY; GENETICS; HIGH THROUGHPUT SEQUENCING; MIDDLE AGED; PATHOLOGY; PROSTATE TUMOR; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; CASE-CONTROL STUDIES; CHROMOSOMAL INSTABILITY; DNA COPY NUMBER VARIATIONS; DNA, NEOPLASM; GENETIC HETEROGENEITY; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HUMANS; KALLIKREINS; MALE; MIDDLE AGED; NEOPLASM GRADING; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 84920538215     PISSN: 00099147     EISSN: 15308561     Source Type: Journal    
DOI: 10.1373/clinchem.2014.226571     Document Type: Article

References (39)

1. Chou R, Croswell JM, Dana T, Bougatsos C, Blazina I, Fu R, et al. Screening for prostate cancer: a review of the evidence for the U.S. Preventive Services Task Force. Ann Intern Med 2011;155:762-71.
2. Stroun M, Anker P, Lyautey J, Lederrey C, Maurice PA. Isolation and characterization of DNA from the plasma of cancer patients. Eur Cancer Clin Oncol 1987;23:707-12.
3. Meyerson M, Pellman D. Cancer genomes evolve by pulverizing single chromosomes. Cell 2011;144:9-10.
4. Thierry AR, Mouliere F, Gongora C, Ollier J, Robert B, Ychou M, et al. Origin and quantification of circulating DNA in mice with human colorectal cancer xenografts. Nucleic Acids Res 2010;38:6159-75.
5. Beck J, Urnovitz HB, Riggert J, Clerici M, Schütz E. Profile of the circulating DNA in apparently healthy individuals. Clin Chem 2009;55:730-8.
6. Lo YM, Chiu RW. Next-generation sequencing of plasma/ serum DNA: an emerging research and molecular diagnostic tool. Clin Chem 2009;55:607-8.
7. Lo YM, Tein MS, Lau TK, Haines CJ, Leung TN, Poon PM, et al. Quantitative analysis of fetal DNA in maternal plasma and serum: implications for noninvasive prenatal diagnosis. Am J Hum Genet 1998;62:768-75.
8. Heitzer E, Ulz P, Belic J, Gutschi S, Quehenberger F, Fischereder K, et al. Tumor-associated copy number changes in the circulation of patients with prostate cancer identified through whole-genome sequencing. Genome Med 2013;5:30.
9. Forshew T, Murtaza M, Parkinson C, Gale D, Tsui DW, Kaper F, et al. Noninvasive identification and monitoring of cancer mutations by targeted deep sequencing of plasma DNA. Sci Transl Med. 2012;4:136ra68.
10. Diaz LA Jr, Bardelli A. Liquid biopsies: genotyping circulating tumor DNA. J Clin Oncol 2014;32:579-86.
11. Leary RJ, Sausen M, Kinde I, Papadopoulos N, Carpten JD, Craig D, et al. Detection of chromosomal alterations in the circulation of cancer patients with whole-genome sequencing. Sci Transl Med 2012;4:162ra154, 1-12.
12. Leary RJ, Kinde I, Diehl F, Schmidt K, Clouser C, Duncan C, et al. Development of personalized tumor biomarkers using massively parallel sequencing. Science Trans Med 2010;2:20ra14, 1-7.
13. van der Vaart M, Semenov DV, Kuligina EV, Richter VA, Pretorius PJ. Characterisation of circulating DNA by parallel tagged sequencing on the 454 platform. Clin Chim Acta 2009;409:21-7.
14. Beck J, Urnovitz HB, Mitchell WM, Schütz E. Next generation sequencing of serum circulating nucleic acids from invasive ductal breast cancer patients reveals differences to healthy and non-malignant controls. Mol Cancer Res 2010;8:335-42.
15. Murtaza M, Dawson SJ, Tsui DW, Gale D, Forshew T, Piskorz AM, et al. Non-invasive analysis of acquired resistance to cancer therapy by sequencing of plasma DNA. Nature 2013;497:108-12.
16. McBride DJ, Orpana AK, Sotiriou C, Joensuu H, Stephens PJ, Mudie LJ, et al. Use of cancer-specific genomic rearrangements to quantify disease burden in plasma from patients with solid tumors. Genes Chromosomes Cancer 2010;49:1062-9.
17. Dawson SJ, Tsui DW, Murtaza M, Biggs H, Rueda OM, Chin SF, et al. Analysis of circulating tumorDNAto monitor metastatic breast cancer. N Engl J Med. 2013;28: 368:1199-209.
18. Bettegowda C, Sausen M, Leary RJ, Kinde I, Wang Y, Agrawal N, et al. Detection of circulating tumor DNA in early-and late-stage human malignancies. Sci Transl Med. 2014;6:224ra24.
19. Newman AM, Bratman SV, To J, Wynne JF, Eclov NC, Modlin LA, et al. An ultrasensitive method for quantitating circulating tumor DNA with broad patient coverage. Nat Med. 2014;20:548-54.
20. Beck J, Hennecke S, Bornemann-Kolatzki K, Urnovitz HB, Neumann S, Ströbel P, et al.Genomeaberrations in canine mammary carcinomas and their detection in cell-free plasma DNA. PLoS One 2013 30;8:e75485.
21. Chan KC, Jiang P, Zheng YW, Liao GJ, Sun H, Wong J, et al. Cancer genome scanning in plasma: detection of tumor-associated copy number aberrations, singlenucleotide variants, and tumoral heterogeneity by massively parallel sequencing. Clin Chem 2013;59: 211-24.
22. Sticker TP, Kumar V. Neoplasia. In: Kumar V, Abbas AK, Fausto N, Aster JC, eds. Robbins and Cotran pathologic basis of disease, 8th Ed. Philadelphia: Elsevier Saunders 2010;259-330.
23. Mitelman F, Johansson B, Mertens F, Eds. Mitelman Database of Chromosome Aberrations and Gene Fusions in Cancer. http://cgap.nci.nih.gov/Chromosomes/Mitelman (Accessed October 2014).
24. Duesberg P, Mandrioli D, McCormack A, Nicholson JM. Is carcinogenesis a form of speciation? Cell Cycle 2011; 10:2100-14.
25. Duesberg P, Iacobuzio-Donahue C, Brosnan JA, Mc-Cormack A, Mandrioli D, Chen L. Origin of metastases: subspecies of cancers generated by intrinsic karyotypic variations. Cell Cycle 2012;11:1151-66.
26. Berger MF, Lawrence MS, Demichelis F, Drier Y, Cibulskis K, Sivachenko AY, et al. The genomic complexity of primary human prostate cancer. Nature 2011;470:214-20.
27. Mandel P, Metais P. Les acides nucléiques du plasma sanguin chez l'homme. C R Seances Soc Biol Fil 1948; 142:241-3.
28. Gal S, Fidler C, Lo YM, Taylor M, Han C, Moore J, et al. Quantitation of circulating DNA in the serum of breast cancer patients by real-time PCR. Br J Cancer 2004;90: 1211-5.
29. Silva JM, Silva J, Sanchez A, Garcia JM, Dominguez G, Provencio M, et al. TumorDNAin plasma at diagnosis of breast cancer patients is a valuable predictor of diseasefree survival. Clin Cancer Res 2002;8:3761-6.
30. Sozzi G, Conte D, Leon M, Ciricione R, Roz L, Ratcliffe C, et al. Quantification of free circulating DNA as a diagnostic marker in lung cancer. J Clin Oncol 2003;21: 3902-8.
31. Lun FM, Tsui NB, Chan KC, Leung TY, Lau TK, Charoenkwan P, et al. Noninvasive prenatal diagnosis of monogenic diseases by digital size selection and relative mutation dosage on DNA in maternal plasma. Proc Natl Acad Sci U S A 2008;105:19920-5.
32. Palomaki GE, Deciu C, Kloza EM, Lambert-Messerlian GM, Haddow JE, Neveux LM, et al. DNA sequencing of maternal plasma reliably identifies trisomy 18 and trisomy 13 as well as Down syndrome: an international collaborative study. Genet Med 2012;14:296-305.
33. Beck J, Urnovitz HB, Groschup MH, Ziegler U, Brenig B, Schütz E. Serum nucleic acids in an experimental bovine transmissible spongiform encephalopathy model. Zoonoses Public Health 2009;56:384-90.
34. Gordon PM, Schütz E, Beck J, Urnovitz HB, Graham C, Clark R, et al. Disease-specific motifs can be identified in circulating nucleic acids from live elk and cattle infected with transmissible spongiform encephalopathies. Nucleic Acids Res 2009;37:550-6.
35. Beck J, Urnovitz HB, Saresella M, Caputo D, Clerici M, Mitchell WM, Schütz E. Serum DNA motifs predict disease and clinical status in multiple sclerosis. J Mol Diagn 2010;12:312-9.
36. Beck J, Schütz E, Urnovitz HB, Tabchy A, Mitchell WM, Mills GB, Meric-Bernstam F. Cell-freeDNAcopy number variations as a marker for breast cancer in a large study cohort [Abstract]. J Clin Oncol 2013;31(15 Suppl). Abstract No. 11013.
37. Mohan S, Heitzer E, Ulz P, Lafer I, Lax S, Auer M, et al. Changes in colorectal carcinoma genomes under anti-EGFR therapy identified by whole-genome plasmaDNA sequencing. PLoS Genet 2014;10:e1004271.
38. Urnovitz HB, Beck J, Bornemann-Kolatzki K, Richardson BE, Lee JH, Mitchell WM, Schütz E. Detection of novel HPV mutations and chromosomal number imbalance (CNI) in laryngeal cancer using next-generation sequencing (NGS) [Abstract]. J Clin Oncol 2014;32(15 Suppl). Abstract No. 6072.
39. Beck J, Gaedcke J, Urnovitz HB, Bornemann-Kolatzki K, Grade M, Mitchell WM, et al. Comprehensive analyses of rectal cancer genomes to reveal copy number variations as potential predictor of induction therapy efficacy [Abstract]. J Clin Oncol 2014;32(15 Suppl). Abstract No. e14549.